physiologically based pharmacokinetic (pbpk) model for biodistribution of radiolabeled peptides in patients with neuroendocrine tumours
Authors
abstract
objective(s): the objectives of this work was to assess the benefits of the application of physiologically based pharmacokinetic (pbpk) models in patients with different neuroendocrine tumours (net) who were treatedwith lu-177 dotatate. the model utilises clinical data on biodistribution of radiolabeled peptides (rlps) obtained by whole body scintigraphy (wbs) of the patients.methods: the blood flow restricted (perfusion rate limited) type of the pbpk model for biodistribution of radiolabeled peptides (rlps) in individual human organs is based on the multi-compartment approach, which takes into account the main physiological processes in the organism: absorption, distribution, metabolism and excretion (adme). the approachcalibrates the pbpk model for each patient in order to increase the accuracy of the dose estimation. datasets obtained using wbs in four patients have been used to obtain the unknown model parameters. the scintigraphic data were acquired using a double head gamma camera in patients with different neuroendocrine tumours who were treated with lu-177 dotatate. the activity administered to each patient was 7400mbq.results: satisfactory agreement of the model predictions with the data obtained from the wbs for each patient has been achieved. conclusion: the study indicates that the pbpk model can be used for more accurate calculation of biodistribution and absorbed doses in patients. this approach is the first attempt of utilizing scintigraphic data in pbpk models, which was obtained during lu-177 peptide therapy of patients with net.
similar resources
Physiologically Based Pharmacokinetic (PBPK) model for biodistribution of radiolabeled peptides in patients with neuroendocrine tumours
Objective(s): The objectives of this work was to assess the benefits of the application of Physiologically Based Pharmacokinetic (PBPK) models in patients with different neuroendocrine tumours (NET) who were treatedwith Lu-177 DOTATATE. The model utilises clinical data on biodistribution of radiolabeled peptides (RLPs) obtained by whole body scintigraphy (WBS) of the patients.Methods: The blood...
full textPhysiologically Based Pharmacokinetic (PBPK) Model for Biodistribution of Radiolabeled Peptides in Patients with Neuroendocrine Tumours
OBJECTIVES The objectives of this work was to assess the benefits of the application of Physiologically Based Pharmacokinetic (PBPK) models in patients with different neuroendocrine tumours (NET) who were treated with Lu-177 DOTATATE. The model utilises clinical data on biodistribution of radiolabeled peptides (RLPs) obtained by whole body scintigraphy (WBS) of the patients. METHODS The blood...
full textProposed Approach to Efficiently Develop Physiologically Based Pharmacokinetic (PBPK) & Physiologically Based Pharmacokinetic-Pharmacodynamic (PBPK-PD) Models for Pesticides
The standard approach to extrapolating from animals to humans (inter-species) or across the human population (intra-species) in risk assessment is to apply 10X uncertainty factors. In Science and Decisions: Advancing Risk Assessment (NRC, 2009), the NAS recommends that the agency “...continue and expand use of the best, most current science to support and revise default assumptions.” EPA publis...
full textDevelopment of a physiologically based pharmacokinetic (PBPK) model for methyl iodide in rats, rabbits, and humans.
Methyl iodide (MeI) has been proposed as an alternative to methyl bromide as a pre-plant soil fumigant that does not deplete stratospheric ozone. In inhalation toxicity studies performed in animals as part of the registration process, three effects have been identified that warrant consideration in developing toxicity reference values for human risk assessment: nasal lesions (rat), acute neurot...
full textThe Implications of Using a Physiologically Based Pharmacokinetic (PBPK) Model for Pesticide Risk Assessment
BACKGROUND A physiologically based pharmacokinetic (PBPK) model would make it possible to simulate the dynamics of chemical absorption, distribution, metabolism, and elimination (ADME) from different routes of exposures and, in theory, could be used to evaluate associations between exposures and biomarker measurements in blood or urine. OBJECTIVE We used a PBPK model to predict urinary excret...
full textMy Resources
Save resource for easier access later
Journal title:
asia oceania journal of nuclear medicine and biologyجلد ۴، شماره ۲، صفحات ۹۰-۹۷
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023